var title_f16_58_17312="Botulinum toxin injection - lateral canthal rhytides";
var content_f16_58_17312=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F50135&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F50135&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 606px\">",
"   <div class=\"ttl\">",
"    Botulinum toxin injection for lateral canthal rhytides",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 586px; height: 191px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Periocular wrinkles at maximal smile are shown before (A) and after (B) treatment with botulinum toxin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_58_17312=[""].join("\n");
var outline_f16_58_17312=null;
var title_f16_58_17313="CRITOE mnemonic for elbow ossification";
var content_f16_58_17313=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F73226&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F73226&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Ossification centers of the elbow",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 487px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The six ossification centers in the pediatric elbow are shown numbered in the order of appearance: Capitellum, radial head,internal (medial) epicondyle, trochlea, olecranon, external (lateral) epicondyle (mnemonic: CRITOE). These secondary ossification centers later fuse to create the mature bony elbow. The salmon shaded regions represent unossified cartilage.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_58_17313=[""].join("\n");
var outline_f16_58_17313=null;
var title_f16_58_17314="JEB non-Herlitz adult nails";
var content_f16_58_17314=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86402&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86402&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Junctional epidermolysis bullosa non-Herlitz",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 363px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Onychodystrophy in an adult individual with JEB non-Herlitz.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_58_17314=[""].join("\n");
var outline_f16_58_17314=null;
var title_f16_58_17315="Patient information: Asthma in children (The Basics)";
var content_f16_58_17315=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15344\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/52/837\">",
"         Asthma and its treatment",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?4/11/4275\">",
"         Patient information: Asthma in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?42/11/43186\">",
"         Patient information: Breathing tests (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?13/7/13427\">",
"         Patient information: Cough in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/47/33522\">",
"         Patient information: Flu (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/22/30052\">",
"         Patient information: Medicines for asthma (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?43/3/44083\">",
"         Patient information: Asthma inhaler techniques in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/0/37892\">",
"         Patient information: Asthma symptoms and diagnosis in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/60/18374\">",
"         Patient information: Asthma treatment in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/26/1442\">",
"         Patient information: Exercise-induced asthma (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/6/31841\">",
"         Patient information: How to use a peak flow meter (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/25/31124\">",
"         Patient information: Trigger avoidance in asthma (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Asthma in children (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/asthma-in-children-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H212326379\">",
"      <span class=\"h1\">",
"       What is asthma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Asthma is a condition that can make it hard to breathe. Asthma does not always cause symptoms. But when a person with asthma has an &ldquo;attack&rdquo; or a flare up, it can be very scary. Asthma attacks happen when the airways in the lungs become narrow and inflamed (",
"      <a class=\"graphic graphic_figure graphicRef65956 \" href=\"UTD.htm?0/52/837\">",
"       figure 1",
"      </a>",
"      ). Asthma can run in families.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H212326386\">",
"      <span class=\"h1\">",
"       What are the symptoms of asthma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Asthma symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Wheezing, or noisy breathing",
"       </li>",
"       <li>",
"        Coughing, often at night or early in the morning, or when you exercise",
"       </li>",
"       <li>",
"        A tight feeling in the chest",
"       </li>",
"       <li>",
"        Trouble breathing",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Symptoms can happen each day, each week, or less often. Symptoms can range from mild to severe. Although rare, an episode of asthma can lead to death.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H212326393\">",
"      <span class=\"h1\">",
"       Is there a test for asthma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor might have your child do a breathing test to see how his or her lungs are working. Most children 6 years old and older can do this test. This test is useful, but it is often normal in children with asthma if they have no symptoms at the time of the test.",
"     </p>",
"     <p>",
"      Your doctor will also do an exam and ask questions such as:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What symptoms does your child have?",
"       </li>",
"       <li>",
"        How often does he or she have the symptoms?",
"       </li>",
"       <li>",
"        Do the symptoms wake him or her up at night?",
"       </li>",
"       <li>",
"        Do the symptoms keep your child from playing or going to school?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H212326400\">",
"      <span class=\"h1\">",
"       How is asthma treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Asthma is treated with different types of medicines. The medicines can be inhalers, liquids, or pills. Your doctor will prescribe medicine based on your child&rsquo;s age and his or her symptoms. Asthma medicines work in one of two ways:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Quick-relief medicines",
"        </strong>",
"        stop symptoms quickly. Doctors prescribe these when children do not have symptoms often. Some children get very active after taking these medicines.",
"       </li>",
"       <li>",
"        <strong>",
"         Long-term controller medicines",
"        </strong>",
"        control asthma and prevent future symptoms. If your child has frequent symptoms or many severe episodes in a year, he or she may need to take these each day.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Almost all children with asthma use an inhaler with a device called a &ldquo;spacer.&rdquo; Some children also need a machine called a &ldquo;nebulizer&rdquo; to breathe in their medicine. Your doctor will show you the right way to use these.",
"     </p>",
"     <p>",
"      It is very important that you give your child all the medicines the doctor prescribes. You might worry about giving a child a lot of medicine. But leaving your child&rsquo;s asthma untreated has much bigger risks than any risks the medicines might have. Asthma that is not treated with the right medicines can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Prevent children from doing normal activities, such as playing sports",
"       </li>",
"       <li>",
"        Make children miss school",
"       </li>",
"       <li>",
"        Damage the lungs",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H212326407\">",
"      <span class=\"h1\">",
"       What is an asthma action plan?",
"      </span>",
"      &nbsp;&mdash;&nbsp;An asthma action plan is a list of instructions that tell you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What medicines your child should use at home each day",
"       </li>",
"       <li>",
"        What warning symptoms to watch for (which suggest that asthma is getting worse)",
"       </li>",
"       <li>",
"        What other medicines to give your child if the symptoms get worse",
"       </li>",
"       <li>",
"        When to get help or call 9-1-1",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You, your child, and your doctor will work together to make an asthma action plan for your child. As part of the action plan, your child may need to use a device called a &ldquo;peak flow meter.&rdquo; This device is used at home to see how well your child&rsquo;s lungs are working. Your doctor will show you and your child the right way to use a peak flow meter.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H212326414\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See a doctor or nurse if your child has an asthma attack and the symptoms do not improve or get worse after using a quick-relief medicine.",
"      <strong>",
"       If the symptoms are severe, call 9-1-1 for an ambulance",
"      </strong>",
"      .",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H212326421\">",
"      <span class=\"h1\">",
"       Can asthma symptoms be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You can help prevent your child&rsquo;s asthma symptoms. You can keep your child away from things that cause or make the symptoms worse. Doctors call these &ldquo;triggers.&rdquo; If you know what your child&rsquo;s triggers are, you can try to avoid them. If you don&rsquo;t know what they are, your doctor can help figure it out.",
"     </p>",
"     <p>",
"      Some common triggers include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Dust and mold",
"       </li>",
"       <li>",
"        Animals, such as dogs and cats",
"       </li>",
"       <li>",
"        Pollen, plants, and trees",
"       </li>",
"       <li>",
"        Cigarette smoke",
"       </li>",
"       <li>",
"        Getting sick with a cold or flu (that&rsquo;s why it&rsquo;s important to get a flu shot each year)",
"       </li>",
"       <li>",
"        Exercise",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you can&rsquo;t avoid certain triggers, talk with your doctor about what you can do. For example, exercise can be good for children with asthma. But your child may need to take an extra dose of his or her inhaler medicine before exercising.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H212326428\">",
"      <span class=\"h1\">",
"       What will my child&rsquo;s life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most children with asthma are able to live normal lives. You can help manage your child&rsquo;s asthma by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Making changes in your life to avoid your child&rsquo;s triggers",
"       </li>",
"       <li>",
"        Keeping track of your child&rsquo;s asthma",
"       </li>",
"       <li>",
"        Having your child use a peak flow meter",
"       </li>",
"       <li>",
"        Following the action plan",
"       </li>",
"       <li>",
"        Telling your doctor when your child&rsquo;s symptoms change",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Sometimes, asthma gets better as children get older. They may not have asthma symptoms when they become adults. But other children can still have asthma when they grow up.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H212326435\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/11/4275?source=see_link\">",
"       Patient information: Asthma in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/47/33522?source=see_link\">",
"       Patient information: Flu (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/7/13427?source=see_link\">",
"       Patient information: Cough in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/11/43186?source=see_link\">",
"       Patient information: Breathing tests (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/22/30052?source=see_link\">",
"       Patient information: Medicines for asthma (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/0/37892?source=see_link\">",
"       Patient information: Asthma symptoms and diagnosis in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/60/18374?source=see_link\">",
"       Patient information: Asthma treatment in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/26/1442?source=see_link\">",
"       Patient information: Exercise-induced asthma (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/25/31124?source=see_link\">",
"       Patient information: Trigger avoidance in asthma (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44083?source=see_link\">",
"       Patient information: Asthma inhaler techniques in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/6/31841?source=see_link\">",
"       Patient information: How to use a peak flow meter (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?16/58/17315?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15344 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-202.43.93.2-04D01F2D42-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_58_17315=[""].join("\n");
var outline_f16_58_17315=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H212326379\">",
"      What is asthma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H212326386\">",
"      What are the symptoms of asthma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H212326393\">",
"      Is there a test for asthma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H212326400\">",
"      How is asthma treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H212326407\">",
"      What is an asthma action plan?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H212326414\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H212326421\">",
"      Can asthma symptoms be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H212326428\">",
"      What will my child&rsquo;s life be like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H212326435\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15344\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/52/837\">",
"      Asthma and its treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/11/4275?source=related_link\">",
"      Patient information: Asthma in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44083?source=related_link\">",
"      Patient information: Asthma inhaler techniques in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/0/37892?source=related_link\">",
"      Patient information: Asthma symptoms and diagnosis in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/60/18374?source=related_link\">",
"      Patient information: Asthma treatment in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/11/43186?source=related_link\">",
"      Patient information: Breathing tests (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/7/13427?source=related_link\">",
"      Patient information: Cough in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/26/1442?source=related_link\">",
"      Patient information: Exercise-induced asthma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/47/33522?source=related_link\">",
"      Patient information: Flu (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/6/31841?source=related_link\">",
"      Patient information: How to use a peak flow meter (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/22/30052?source=related_link\">",
"      Patient information: Medicines for asthma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/25/31124?source=related_link\">",
"      Patient information: Trigger avoidance in asthma (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_58_17316="Postinflammatory hyperpigmentation in acne";
var content_f16_58_17316=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F58817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F58817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Postinflammatory hyperpigmentation and scarring in acne vulgaris",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple hyperpigmented macules and scars are present in this woman with acne vulgaris.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_58_17316=[""].join("\n");
var outline_f16_58_17316=null;
var title_f16_58_17317="Amiloride: Pediatric drug information";
var content_f16_58_17317=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Amiloride: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"    see \"Amiloride: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/32/3589?source=see_link\">",
"    see \"Amiloride: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F133045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Amiloride&reg;;",
"     </li>",
"     <li>",
"      Midamor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1056427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihypertensive Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Diuretic, Potassium Sparing",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1056420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"      see \"Amiloride: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypertension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 0.4-0.625 mg/kg/day; maximum dose: 20 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 5-10 mg/day in 1-2 divided doses (JNC 7)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edema:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 6-20 kg: 0.625 mg/kg/day in 1-2 divided doses; maximum dose: 10 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;20 kg and Adults: 5-10 mg/day in 1-2 divided doses; maximum dose: 20 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer at 50% of normal dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Avoid use",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F133018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F133003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1056431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with food or milk",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1056430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of edema associated with CHF, hepatic cirrhosis, and hyperaldosteronism; hypertension; primary hyperaldosteronism; hypokalemia induced by kaliuretic diuretics",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F133089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       AMILoride may be confused with amiodarone, amLODIPine, inamrinone",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F133087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fatigue, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dehydration, gynecomastia, hyperchloremic metabolic acidosis, hyperkalemia, hyponatremia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, appetite changes, constipation, diarrhea, gas pain, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle cramps, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Alopecia, arrhythmia, bladder spasms, chest pain, dyspnea, dysuria, GI bleeding, intraocular pressure increased, jaundice, orthostatic hypotension, palpitation, polyuria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1056436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to amiloride or any component; hyperkalemia; anuria, acute or chronic renal insufficiency, and evidence of diabetic nephropathy; concomitant use of potassium supplements (except in severe and/or refractory hypokalemia) or potassium-sparing diuretics",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1056419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with dehydration, electrolyte imbalance, metabolic or respiratory acidosis, diabetes (particularly those with nephropathy), hyponatremia, impaired renal function, or hepatic dysfunction; patients receiving potassium or other potassium-sparing diuretics; use with caution and modify dosage in patients with decreased renal function",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1056418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe hyperkalemia can occur",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Incidence is greater in patients with renal impairment, diabetes mellitus, and in elderly patients. Serum potassium levels must be monitored at frequent intervals especially when dosages are changed or with any illness that may cause renal dysfunction. Amiloride should be discontinued in diabetic patients for at least 3 days prior to glucose tolerance testing; discontinue if serum potassium &gt;5.5 mEq/L; risk of hyperkalemia is reduced with concomitant use of thiazide diuretic.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F133012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Potassium-Sparing Diuretics may enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: Potassium-Sparing Diuretics may enhance the adverse/toxic effect of Ammonium Chloride. Specifically the risk of systemic acidosis.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Canagliflozin may enhance the hypotensive effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Potassium-Sparing Diuretics may diminish the therapeutic effect of Cardiac Glycosides. In particular, the inotropic effects of digoxin appear to be diminished. Potassium-Sparing Diuretics may increase the serum concentration of Cardiac Glycosides. This particular effect may be unique to Spironolactone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Potassium-Sparing Diuretics may enhance the hyperkalemic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: AMILoride may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drospirenone: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Potassium-Sparing Diuretics may diminish the therapeutic effect of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Potassium-Sparing Diuretics may enhance the hyperkalemic effect of Tacrolimus (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1056439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid natural licorice (causes sodium and water retention and increases potassium loss) and salt substitutes; food decreases absorption to &sim;30%",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F133014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4930891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1056426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum potassium, sodium, creatinine, BUN, blood pressure, fluid balance",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1056417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acts directly on the distal renal tubule to inhibit sodium-potassium ion exchange; decreases sodium reabsorption in the distal tubule by inhibiting cellular sodium transport mechanisms such as the conductive sodium influx pathway and possibly the sodium-hydrogen ion exchange system; also inhibits hydrogen ion secretion; its diuretic activity is",
"     <b>",
"      independent",
"     </b>",
"     of aldosterone.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1056434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: 6-10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1056435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Adults: V",
"     <sub>",
"      d",
"     </sub>",
"     : 350-380 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: No active metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Normal renal function: 6-9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     End-stage renal disease: 21-144 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Unchanged drug, equally in urine and feces",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1056425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/32/3589?source=see_link\">",
"      see \"Amiloride: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Report to your physician any muscle cramps, weakness, nausea, or dizziness; may cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1056437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Studies utilizing aerosolized amiloride (5 mmol/L in 0.3% saline) in adult cystic fibrosis patients (Tomkiewicz, 1993) have suggested that inhaled amiloride is capable of improving the rheologic properties of the abnormally thickened mucus by increasing mucus sodium content",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F11308003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 1 mg/mL oral suspension may be made with tablets. Crush ten 5 mg tablets in a mortar and reduce to a fine powder. Add small proportions up to 20 mL of Glycerin BP or Glycerin, USP and mix to uniform paste; mix while adding sterile water in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     50 mL; transfer to a calibrated bottle, rinse mortar with sterile water, and add quantity of sterile water sufficient to make 50 mL. Label &ldquo;shake well&rdquo; and &ldquo;refrigerate&rdquo;. Stable for 21 days.",
"    </p>",
"    <div class=\"reference\">",
"     Nahata MC, Pai VB, and Hipple TF,",
"     <i>",
"      Pediatric Drug Formulations",
"     </i>",
"     , 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/58/17317/abstract-text/12748199 /pubmed\" id=\"12748199 \" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, \"The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/58/17317/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tomkiewicz RP, App, EM, Zayas JG, et al, &ldquo;Amiloride Inhalation Therapy in Cystic Fibrosis. Influence on Ion Content, Hydration, and Rheology of Sputum,&rdquo;",
"      <i>",
"       Am Rev Resp Dis,",
"      </i>",
"      1993, 148:1002-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/58/17317/abstract-text/8214916/pubmed\" id=\"8214916\" target=\"_blank\">",
"        8214916",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van der Vorst MM, Kist JE, van der Heijden AJ, et al, \"Diuretics in Pediatrics: Current Knowledge and Future Prospects,\"",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2006, 8(4):245-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/58/17317/abstract-text/16898855/pubmed\" id=\"16898855\" target=\"_blank\">",
"        16898855",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12556 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-62E4DD783C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_58_17317=[""].join("\n");
var outline_f16_58_17317=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708618\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133045\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056427\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056420\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133018\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133003\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056431\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056430\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133089\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133087\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056436\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056419\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056418\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298733\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133012\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056439\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133014\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4930891\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056426\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056417\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056434\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056435\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056425\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056437\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11308003\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12556\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12556|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=related_link\">",
"      Amiloride: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/32/3589?source=related_link\">",
"      Amiloride: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_58_17318="General principles of acute fracture management";
var content_f16_58_17318=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   General principles of acute fracture management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/58/17318/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/58/17318/contributors\">",
"     Richard Derby, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/58/17318/contributors\">",
"     Anthony Beutler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/58/17318/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/58/17318/contributors\">",
"     Patrice Eiff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/58/17318/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/58/17318/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/58/17318/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with suspected fractures require urgent and sometimes emergent evaluation to determine if serious complicating conditions exist. Such conditions, including any neurovascular injury, often require immediate surgical consultation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/58/17318/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Nevertheless, many fractures are uncomplicated and can be managed effectively in a non-surgical setting.",
"   </p>",
"   <p>",
"    The acute management of uncomplicated fractures is reviewed below and involves the following steps:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Initial clinical assessment",
"     </li>",
"     <li>",
"      Radiographic assessment",
"     </li>",
"     <li>",
"      Immobilization",
"     </li>",
"     <li>",
"      Pain management",
"     </li>",
"     <li>",
"      Patient education and follow-up care",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Basic concepts of fracture healing, the proper way to describe fractures based upon clinical findings and radiographic appearance, pediatric fracture management, and the basic principles of long-term fracture management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43941?source=see_link\">",
"     \"General principles of fracture management: Bone healing and fracture description\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20104?source=see_link\">",
"     \"General principles of fracture management: Fracture patterns and description in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/23/1400?source=see_link\">",
"     \"General principles of definitive fracture management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INITIAL CLINICAL ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician begins the assessment of any patient who has sustained significant trauma by looking for life-threatening injuries using the basic approach outlined in Advanced Trauma Life Support&trade;. Patients presenting to a clinic following major trauma or who appear to have sustained significant injury are best transferred to the emergency department for thorough evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients without apparent life-threatening injuries who appear appropriate for office management, assessment begins with a focused history. Analgesia is sometimes needed before a history can be obtained.",
"   </p>",
"   <p>",
"    The history should generally include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mechanism of injury",
"     </li>",
"     <li>",
"      Significant past injuries or surgeries in the affected area",
"     </li>",
"     <li>",
"      Concomitant injuries (\"Did you injure any other part of your body?\")",
"     </li>",
"     <li>",
"      Chronic medical conditions and medications",
"     </li>",
"     <li>",
"      Allergies",
"     </li>",
"     <li>",
"      Last meal (in case an injury requiring urgent surgery is identified)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Details of the mechanism of injury and an understanding of the injury patterns associated with particular mechanisms are important. Injury patterns guide the examination and choice of radiologic studies. Often they help the clinician to consider less obvious associated injuries to bones, ligaments, or tendons.",
"   </p>",
"   <p>",
"    As an example, falling onto an outstretched hand (FOOSH) is most often associated with a distal radius fracture but may also cause an occult metacarpal or scaphoid fracture. Any patient with radial-sided wrist pain after FOOSH requires careful examination of the entire hand and wrist, including the scaphoid bone. Specific scaphoid radiographs are performed on any patient with \"snuffbox\" tenderness (ie, tenderness over the scaphoid in the area between the abductor pollicis longus and extensor pollicis longus). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/13/21722?source=see_link\">",
"     \"Distal radius fractures in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1848?source=see_link\">",
"     \"Scaphoid fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the patient's history and injury mechanism guide the examination, a general assessment of the involved region should always be performed. This includes evaluating neurovascular function and looking for signs of soft tissue damage and breaks in the skin over the area of injury, which suggests the presence of an open fracture. The neurovascular examination includes palpating distal pulses, measuring capillary refill, and testing motor function, sensation, and two point discrimination distal to the fracture site.",
"   </p>",
"   <p>",
"    Palpate the entire area around the fracture site to exclude adjacent injuries. This includes the entire bone in question, adjacent bones, and at least one joint above and below the injury site. Avoid testing range of motion or moving the affected area or limb until radiologic assessment is completed in order to prevent exacerbating fracture displacement, soft tissue damage, or neurovascular compromise [",
"    <a class=\"abstract\" href=\"UTD.htm?16/58/17318/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The general rule of fracture immobilization is \"splint it where it lies.\" The major exception to this rule occurs when distal neurovascular function is not intact. If pulses are undetectable, motor function is absent, or other signs of significant distal neurovascular compromise exist, the physician should promptly reduce any apparent dislocation or reposition the injured extremity. If neurovascular function improves following repositioning, the injury should immediately be splinted in this new position, neurovascular status verified following splint application, and emergent surgical consultation obtained so definitive care can be provided. If neurovascular status does not improve despite repeated attempts at reduction, the injury is splinted in the position of maximum neurovascular function and emergently transferred for definitive care.",
"   </p>",
"   <p>",
"    In skeletally immature patients, the clinician must be alert to the possibility of physeal injury. Proper identification and treatment of growth plate fractures is essential to minimize the risk of growth arrest or asymmetric bone growth [",
"    <a class=\"abstract\" href=\"UTD.htm?16/58/17318/abstract/1,3,4\">",
"     1,3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20104?source=see_link\">",
"     \"General principles of fracture management: Fracture patterns and description in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     INITIAL RADIOLOGIC ASSESSMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11045305\">",
"    <span class=\"h2\">",
"     Plain radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A basic discussion of how to describe fractures and bone radiographs is found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43941?source=see_link\">",
"     \"General principles of fracture management: Bone healing and fracture description\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Three guidelines are helpful when obtaining x-rays of a potential fracture site:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obtain multiple and orthogonal views &ndash; \"One view is no view\" is a common radiologic maxim. Two orthogonal views are the absolute minimum needed for adequate assessment.",
"     </li>",
"     <li>",
"      Ensure radiographs are of high quality (proper angle, technique, and exposure) and include the entire bone or joint in question.",
"     </li>",
"     <li>",
"      Obtain advanced imaging when clinical findings suggest fracture but plain x-rays are unrevealing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Orthogonal views are x-rays taken at 90 degrees to each other; most often these consist of an anterior-posterior (AP) and lateral view. However, in some situations, AP and lateral views alone are insufficient to diagnose obscure fractures and x-rays using particular perspectives are needed. As examples, a scaphoid view may reveal a scaphoid fracture not seen on a standard AP radiograph of the wrist, while a fracture of the hook of the hamate may be apparent only on a carpal tunnel view. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1848?source=see_link\">",
"     \"Scaphoid fractures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9620?source=see_link\">",
"     \"Hamate fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fractures can sometimes be difficult to see on the best of radiographs. Hence, x-rays that are over- or underpenetrated, improperly angled (eg, not true laterals), omit important anatomy, or contain overlying shadows can hinder diagnosis and should not be accepted. Radiographs of a specific bone or joint should include the entire structure.",
"   </p>",
"   <p>",
"    Stress fractures, scaphoid fractures, physeal fractures, hip fractures in the elderly, and many other bony injuries may not appear on initial plain radiographs. Computed tomography (CT) and magnetic resonance imagining (MRI) reveal occult fractures in many such cases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/58/17318/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. An alternative approach is to assume the presence of a fracture, treat the injury accordingly, and obtain follow-up x-rays a week or two later. Many occult injuries become apparent on subsequent radiographs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11045313\">",
"    <span class=\"h2\">",
"     Musculoskeletal ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Musculoskeletal ultrasound is not the imaging modality of choice for the diagnosis of fractures, but can be useful in some settings due to its portability, increasing availability, and lack of ionizing radiation. It is often used to make rapid assessments in the military setting, emergency departments, sports medicine clinics, and ski resort medical stations. According to a systematic review of eight studies involving varying methods and different extremity fractures, the sensitivity of ultrasound to detect an extremity fracture ranges from 85 to 100 percent, while specificity ranges from 73 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/58/17318/abstract/6\">",
"     6",
"    </a>",
"    ]. Sonography may also be useful for identifying some non-extremity fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?16/58/17318/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     IMMOBILIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fracture immobilization is of benefit in the great majority of cases. It prevents fracture displacement or loss of reduction, protects the area from further injury, and reduces pain. Several methods can be used to immobilize uncomplicated fractures, including splinting, casting, bracing, buddy taping, and sling and swathe (",
"    <a class=\"graphic graphic_picture graphicRef55706 \" href=\"UTD.htm?22/2/22565\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef72212 \" href=\"UTD.htm?41/20/42304\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef79535 \" href=\"UTD.htm?21/8/21635\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef78370 \" href=\"UTD.htm?26/7/26736\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In the acute setting, splinting is the preferred method for immobilizing fractures that are at low risk for displacement primarily because of the soft tissue swelling that develops around most fracture sites. A cast applied to the site of an acute injury cannot accommodate such swelling, and can lead to tissue ischemia, pressure-related injury, and even iatrogenic compartment syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?16/58/17318/abstract/8\">",
"     8",
"    </a>",
"    ]. Conversely, a cast applied to an already swollen extremity may become loose as swelling subsides, providing inadequate support and immobilization. Additional benefits of splinting include the relative ease of application, lower risk of skin breakdown, and improved hygiene [",
"    <a class=\"abstract\" href=\"UTD.htm?16/58/17318/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Certain unstable fractures may require acute casting or operative fixation to prevent displacement. Such fractures may include those that required reduction, fracture dislocations, segmental or spiral fractures, and simultaneous fractures of both the ulna and radius [",
"    <a class=\"abstract\" href=\"UTD.htm?16/58/17318/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A thorough discussion of fracture splinting, including equipment, techniques, and complications, is found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=see_link\">",
"     \"Splinting of musculoskeletal injuries\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PAIN MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adequate analgesia is an important aspect of acute fracture management. Fracture immobilization, ice, elevation of the affected limb, and analgesic medications all reduce pain. Splinting prevents motion at the fracture site, which is a major source of pain. The noncircumferential nature of splints allows ice to be placed in nearly direct contact with the injured tissue. Additional reduction in swelling and pain may be achieved by elevating the fracture site above the level of the heart.",
"   </p>",
"   <p>",
"    Initially, analgesics are often required for effective pain control. For minor fractures,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    or a non-steroidal antiinflammatory drug (NSAID) is often sufficient for adequate analgesia, but opioids may be required and should be used if necessary. The potential effects of NSAIDs on fracture healing are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link&amp;anchor=H23#H23\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\", section on 'Possible effect on fracture healing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute fracture pain lasts from a few days to a week. Pain that persists or increases after this initial period may represent a complication and should be investigated. Such complications may include acute compartment syndrome, pressure-related injuries of the skin and soft tissue, and movement or displacement at the fracture site due to inadequate immobilization [",
"    <a class=\"abstract\" href=\"UTD.htm?16/58/17318/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=see_link\">",
"     \"Acute compartment syndrome of the extremities\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Delayed complications related to a cast or splint may also manifest as worsening pain. Any patient with a splint or cast who complains of new or worsening pain in that region should be urgently assessed. Fracture care providers must ensure that patients have 24 hour access to facilities where casts can be removed and fractures evaluated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PATIENT EDUCATION AND FOLLOW-UP CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a fracture and any associated injuries have been stabilized, the clinician must provide clear instructions for injury care and monitoring, including cast or splint care, and a follow-up plan must be in place. For uncomplicated fractures, a return visit should take place within three to seven days. Earlier follow-up may be necessary if a cast was applied.",
"   </p>",
"   <p>",
"    All patients should be given verbal and printed instructions explaining the signs and symptoms indicating that immediate reevaluation is needed. Such signs include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      New or worsening pain",
"     </li>",
"     <li>",
"      Diminished circulation in the affected extremity (cool or dusky digits, diminished capillary refill)",
"     </li>",
"     <li>",
"      Diminished motor function in the affected extremity (no longer able to move digits)",
"     </li>",
"     <li>",
"      Bleeding or discharge from the cast or splint",
"     </li>",
"     <li>",
"      Feelings of pressure, grinding, or numbness in the area of the fracture",
"     </li>",
"     <li>",
"      Significant damage to the cast or splint",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The printed instructions should also contain telephone numbers for follow-up and directions for splint and cast care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/51/11058?source=see_link\">",
"       \"Patient information: Cast and splint care (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=see_link\">",
"       \"Patient information: Cast and splint care (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Begin the assessment of any patient who has sustained significant trauma by looking for life-threatening injuries. Patients presenting to a clinic following major trauma or who appear to have sustained significant injury are best transferred to the emergency department.",
"     </li>",
"     <li>",
"      The history of any patient with a potential fracture should generally include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Mechanism of injury",
"     </li>",
"     <li>",
"      Significant past injuries or surgeries in the affected area",
"     </li>",
"     <li>",
"      Concomitant injuries (\"Did you injure any other part of your body?\")",
"     </li>",
"     <li>",
"      Chronic medical conditions and medications",
"     </li>",
"     <li>",
"      Allergies",
"     </li>",
"     <li>",
"      Last meal (in case an injury requiring urgent surgery is identified) (see",
"      <a class=\"local\" href=\"#H3\">",
"       'History'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The history and injury mechanism guide the physical examination of patients with a possible fracture. A general assessment of the involved region should always be performed, including evaluation of neurovascular function and investigation for signs of soft tissue damage and breaks in the skin over the area of injury, which suggests the presence of an open fracture. Palpate the entire area around the fracture site, including the entire bone in question, adjacent bones, and at least one joint above and below the injury site. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Three basic principles are helpful when obtaining x-rays of a potential fracture:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Obtain multiple and orthogonal views &ndash; \"One view is no view\" is a common radiologic maxim. Two orthogonal views are the absolute minimum needed for adequate assessment.",
"     </li>",
"     <li>",
"      Ensure radiographs are of high quality (proper angle, technique, and exposure) and include the entire bone or joint in question.",
"     </li>",
"     <li>",
"      Obtain advanced imaging when clinical findings suggest fracture but plain x-rays are unrevealing. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Initial radiologic assessment'",
"      </a>",
"      above.) A basic discussion of how to describe fractures and bone radiographs is found separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43941?source=see_link\">",
"       \"General principles of fracture management: Bone healing and fracture description\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fracture immobilization is of benefit in the great majority of cases. It prevents fracture displacement or loss of reduction, protects the area from further injury, and reduces pain. Several methods can be used, but in the acute setting splinting is generally preferred. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Immobilization'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=see_link\">",
"       \"Splinting of musculoskeletal injuries\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Adequate analgesia is an important aspect of acute fracture management. Fracture immobilization, ice, elevation of the affected limb, and analgesic medications all reduce pain. For minor fractures,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      or a non-steroidal antiinflammatory drug (NSAID) is often sufficient for adequate analgesia, but opioids may be required and should be used if necessary. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pain management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After initial evaluation and treatment is completed, the clinician must provide clear instructions for injury care and monitoring, including cast or splint care, and a follow-up plan must be in place. For uncomplicated fractures, a return visit should take place within three to seven days. Earlier follow-up may be necessary if a cast was applied. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Patient education and follow-up care'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Eiff PM, Hatch RL. Fracture Management for Primary Care, 3rd, WB Saunders, Philadelphia 2011.",
"    </li>",
"    <li>",
"     DeLee JC, Drez D Jr. DeLee &amp; Drez's Orthopaedic Sports Medicine: Principles and Practice, 3rd, WB Saunders, Philadelphia 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/58/17318/abstract/3\">",
"      Benjamin, HJ, Hang, BT. Common acute upper extremity injuries in sports. Clin Ped Emerg Med 2007; 8:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/58/17318/abstract/4\">",
"      Malanga GA, Ramirez-Del Toro JA. Common injuries of the foot and ankle in the child and adolescent athlete. Phys Med Rehabil Clin N Am 2008; 19:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/58/17318/abstract/5\">",
"      Ahn JM, El-Khoury GY. Occult fractures of extremities. Radiol Clin North Am 2007; 45:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/58/17318/abstract/6\">",
"      Joshi N, Lira A, Mehta N, et al. Diagnostic accuracy of history, physical examination, and bedside ultrasound for diagnosis of extremity fractures in the emergency department: a systematic review. Acad Emerg Med 2013; 20:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/58/17318/abstract/7\">",
"      Chan SS. Emergency bedside ultrasound for the diagnosis of rib fractures. Am J Emerg Med 2009; 27:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/58/17318/abstract/8\">",
"      Newton EJ, Love J. Acute complications of extremity trauma. Emerg Med Clin North Am 2007; 25:751.",
"     </a>",
"    </li>",
"    <li>",
"     Mazzola TJ. Splint and casting. In: The Sports Medicine Resouce Manual, Seidenberg PS, Beutler AI (Eds), WB Saunders, Philadelphia 2007. p.152.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 237 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-8913731101-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_58_17318=[""].join("\n");
var outline_f16_58_17318=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INITIAL CLINICAL ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      INITIAL RADIOLOGIC ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11045305\">",
"      Plain radiographs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11045313\">",
"      Musculoskeletal ultrasound",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      IMMOBILIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PAIN MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PATIENT EDUCATION AND FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/237\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/237|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/7/26736\" title=\"figure 1\">",
"      Sling and swathe splint",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/237|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/2/22565\" title=\"picture 1\">",
"      Short leg splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/20/42304\" title=\"picture 2\">",
"      Short arm cast 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/8/21635\" title=\"picture 3\">",
"      Finger buddy taping",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=related_link\">",
"      Acute compartment syndrome of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/13/21722?source=related_link\">",
"      Distal radius fractures in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/23/1400?source=related_link\">",
"      General principles of definitive fracture management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43941?source=related_link\">",
"      General principles of fracture management: Bone healing and fracture description",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20104?source=related_link\">",
"      General principles of fracture management: Fracture patterns and description in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9620?source=related_link\">",
"      Hamate fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=related_link\">",
"      Patient information: Cast and splint care (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/51/11058?source=related_link\">",
"      Patient information: Cast and splint care (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1848?source=related_link\">",
"      Scaphoid fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=related_link\">",
"      Splinting of musculoskeletal injuries",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_58_17319="Stress urinary incontinence in women: Preoperative evaluation for a primary procedure";
var content_f16_58_17319=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Stress urinary incontinence in women: Preoperative evaluation for a primary procedure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/58/17319/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/58/17319/contributors\">",
"     J Eric Jelovsek, MD, MMEd, FACOG, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/58/17319/contributors\">",
"     Jhansi Reddy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/58/17319/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/58/17319/contributors\">",
"     Linda Brubaker, MD, FACS, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/58/17319/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/58/17319/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/58/17319/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 24, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stress urinary incontinence (SUI), the involuntary leakage of urine on effort or exertion, or on sneezing or coughing, affects 4 to 35 percent of women [",
"    <a class=\"abstract\" href=\"UTD.htm?16/58/17319/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Conservative approaches to treatment of SUI include pelvic floor muscle training and incontinence pessaries. However, for women who fail or decline conservative therapy, there are a variety of surgical treatments. Preoperative evaluation of women with SUI helps to exclude other diagnoses and guide the choice of a surgical procedure.",
"   </p>",
"   <p>",
"    The preoperative evaluation of women with SUI will be reviewed here. General principles of evaluation of women with urinary incontinence and conservative and surgical treatment of SUI, as well as evaluation of women with recurrent SUI after surgery, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29929?source=see_link\">",
"     \"Clinical presentation and diagnosis of urinary incontinence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=see_link\">",
"     \"Treatment of urinary incontinence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43177?source=see_link\">",
"     \"Stress urinary incontinence in women: Choosing a primary surgical procedure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/23/44409?source=see_link\">",
"     \"Stress urinary incontinence in women: Persistent/recurrent symptoms after surgical treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continence is achieved when the urethra maintains a pressure greater than bladder pressure (eg, during a detrusor muscle contraction or an increase in intraabdominal pressure). Loss of the urethra's ability to maintain the required pressure results from anatomic or neurologic defects.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The anatomic contribution to continence involves the anterior vaginal wall and overlying connective tissue, which provide the urethra with a stable base upon which to rest (hammock theory [",
"      <a class=\"abstract\" href=\"UTD.htm?16/58/17319/abstract/3\">",
"       3",
"      </a>",
"      ]). Upon an increase in bladder or intraabdominal pressure, the urethra is compressed onto this base, thereby closing the lumen and maintaining urethral pressure. When the support structures are weakened, the urethra loses its underlying support and becomes hypermobile. Thus, the normal mechanism of continence through urethral compression is compromised.",
"      <br/>",
"      <br/>",
"      Etiologies of loss of urethral support include",
"      <span class=\"nowrap\">",
"       pregnancy/childbirth,",
"      </span>",
"      aging, and repetitive stress on the pelvic floor (eg, repetitive heavy lifting, chronic cough, or obesity). Genetic factors may also contribute to a loss of pelvic support through deficient collagen structure.",
"     </li>",
"     <li>",
"      The neurologic component of continence is mediated through both bladder and urethral innervation. The bladder storage and filling phase is controlled through a spinal sympathetic reflex that (1) stimulates beta adrenergic receptors within the bladder wall causing relaxation of the smooth muscle and (2) activates alpha adrenergic receptors in the urethra which contract the urethra and increase its pressure. The urethra is also innervated through efferent pathways from the pudendal nerve, which increases the tone of the pelvic diaphragm and striated urethral sphincter. Pregnancy, childbirth, and aging can result in pudendal neuropathy leading to urinary incontinence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of pregnancy and childbirth in the development of stress urinary incontinence (SUI) is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/18/19753?source=see_link\">",
"     \"Pelvic floor disorders associated with pregnancy and childbirth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of stress urinary incontinence (SUI) is made by a combination of history and urinary stress testing. Additional office testing and urodynamic studies are useful for some women who are planning anti-incontinence surgery.",
"   </p>",
"   <p>",
"    SUI often coexists with pelvic organ prolapse",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anal incontinence [",
"    <a class=\"abstract\" href=\"UTD.htm?16/58/17319/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. The possible presence of these disorders should be assessed during the history and physical examination, as they may alter surgical decision making. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40473?source=see_link&amp;anchor=H21524755#H21524755\">",
"     \"An overview of the epidemiology, risk factors, clinical manifestations, and management of pelvic organ prolapse in women\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22458?source=see_link&amp;anchor=H17#H17\">",
"     \"Fecal incontinence in adults\", section on 'Evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43177?source=see_link&amp;anchor=H14#H14\">",
"     \"Stress urinary incontinence in women: Choosing a primary surgical procedure\", section on 'Choosing a procedure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MEDICAL AND VOIDING HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical and voiding history are used to ensure that the patient's symptoms are consistent with stress urinary incontinence (SUI) and to exclude a non-stress etiology of urinary incontinence.",
"   </p>",
"   <p>",
"    A urinary history is taken during a patient interview or using a questionnaire (",
"    <a class=\"graphic graphic_figure graphicRef78721 \" href=\"UTD.htm?27/23/28021\">",
"     figure 1",
"    </a>",
"    ). Typical symptoms of SUI are involuntary urine loss, such as leakage of urine with increased intraabdominal pressure, ie, coughing, sneezing, laughing, or physical exertion. A bladder diary (",
"    <a class=\"graphic graphic_figure graphicRef69130 \" href=\"UTD.htm?4/30/4591\">",
"     figure 2",
"    </a>",
"    ) can be useful, particularly in patients in whom the etiology of urinary incontinence is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29929?source=see_link\">",
"     \"Clinical presentation and diagnosis of urinary incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women who leak urine",
"    <strong>",
"     without",
"    </strong>",
"    increased abdominal pressure, particularly upon standing, or have frequent nocturia (&ge;2 episodes per night) should be evaluated with urodynamic testing for urge incontinence, overflow incontinence, intrinsic sphincter deficiency, or high urine output (eg, due to high fluid intake or the rare case of diabetes insipidus). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29929?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical presentation and diagnosis of urinary incontinence\", section on 'Types of urinary incontinence'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43177?source=see_link&amp;anchor=H24#H24\">",
"     \"Stress urinary incontinence in women: Choosing a primary surgical procedure\", section on 'Lack of urethral hypermobility and intrinsic sphincter deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A focused medical history is taken to exclude local or systemic conditions that may cause or worsen urinary incontinence (",
"    <a class=\"graphic graphic_table graphicRef82618 graphicRef60839 \" href=\"UTD.htm?13/61/14301\">",
"     table 1A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef80413 \" href=\"UTD.htm?3/11/3261\">",
"     table 2",
"    </a>",
"    ). In addition, the history should focus on factors that impact surgical risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29929?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical presentation and diagnosis of urinary incontinence\", section on 'History'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41735?source=see_link\">",
"     \"Overview of the principles of medical consultation and perioperative medicine\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PELVIC EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete pelvic examination is performed to quantify pelvic organ support according to the pelvic organ prolapse quantitation system (POP-Q) and to exclude a urethral or pelvic mass. A urethral mass could be a urethral diverticulum or, rarely, a neoplasm. A pelvic mass (eg, an anterior uterine leiomyoma) may exert pressure upon the bladder and exacerbate stress urinary incontinence (SUI). If pooling of urine is noted in the vagina, the patient should be evaluated for a urinary tract fistula. In addition, for women who have undergone previous vaginal surgery, the presence or absence of prior surgical materials (eg, suture, mesh) should be noted. The technique for pelvic examination and evaluation for urethral diverticulum and urinary tract fistula are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/46/8937?source=see_link\">",
"     \"Pelvic organ prolapse in women: Diagnostic evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42681?source=see_link\">",
"     \"The gynecologic history and pelvic examination\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26873?source=see_link\">",
"     \"Urethral diverticulum in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44792?source=see_link\">",
"     \"Urogenital tract fistulas in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Physical examination to exclude systemic conditions associated with urinary incontinence is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29929?source=see_link\">",
"     \"Clinical presentation and diagnosis of urinary incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     OFFICE TESTING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Urinary stress test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Confirmation of the diagnosis of stress urinary incontinence (SUI) includes visualizing leakage of urine from the urethra during a urinary stress test (also referred to as a cough stress test or cough test). Instantaneous leakage with cough suggests SUI. Delayed leakage suggests detrusor overactivity incontinence, especially if there is a large flow of leakage that is difficult for the patient to stop.",
"   </p>",
"   <p>",
"    The urinary stress test consists of having a patient with a full bladder Valsalva (tense her abdominal muscles) or cough. We routinely have patients present to the office with a full bladder. Alternatively, a patient's bladder can also be filled with sterile water using a catheter. If the bladder is filled, the patient's first bladder sensation and maximum capacity are noted. Maximum capacity in most women is 200 to 300 mL. The technique for performing a urinary stress test is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29929?source=see_link\">",
"     \"Clinical presentation and diagnosis of urinary incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1568119\">",
"    <span class=\"h2\">",
"     Assessing urethral mobility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urethral hypermobility (also referred to as bladder neck hypermobility) is present in most women who have primary SUI. In our practice, we no longer formally test for urethral hypermobility, since the presence or absence of hypermobility does not appear to change management. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Urodynamic testing'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43177?source=see_link&amp;anchor=H24#H24\">",
"     \"Stress urinary incontinence in women: Choosing a primary surgical procedure\", section on 'Lack of urethral hypermobility and intrinsic sphincter deficiency'",
"    </a>",
"    .) Historically, the urethral cotton swab test (Q-tip&reg; test) was the most common test used to evaluate urethral mobility for gynecologists, while urology used fluoroscopy. However, the cotton swab test has questionable test-retest and interobserver reliability [",
"    <a class=\"abstract\" href=\"UTD.htm?16/58/17319/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. It is not possible to assess the accuracy of this and other tests of urethral hypermobility, since there is no accepted gold standard.",
"   </p>",
"   <p>",
"    Some clinicians assess for urethral hypermobility solely by assessing the severity of point Aa prolapse (stage II or higher is a positive test). This approach appears to be most accurate in women with advanced prolapse. Studies have demonstrated that almost all (over 90 percent) women with advanced point Aa prolapse will have a positive cotton swab test [",
"    <a class=\"abstract\" href=\"UTD.htm?16/58/17319/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. Overall, the role of urethral hypermobility testing is currently limited and unlikely to change management.",
"   </p>",
"   <p>",
"    Pelvic sonography is under investigation as a non-invasive alternative for assessing urethral hypermobility, but its role in changing surgical management is currently unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?16/58/17319/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Postvoid residual volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of the postvoid residual volume (PVR) is performed to exclude overflow incontinence or other types of voiding dysfunction. To measure the PVR, the patient is asked to start with a full bladder and void as she normally would (without additional effort to fully empty the bladder). The residual urine in the bladder is measured either by catheterization or bladder sonography. Normally, women should be able to void at least 80 percent of the total bladder volume and have residual urine less than 50 cc immediately after voiding. In general, a PVR of greater than 200 cc may be suggestive of voiding dysfunction or detrusor weakness; the range of normal values for PVR and treatment options remains controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?16/58/17319/abstract/15-17\">",
"     15-17",
"    </a>",
"    ] (these values may vary in elderly women or those with advanced pelvic organ prolapse).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Urine culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary tract infection should be excluded in all women with urinary incontinence. If a sample for urine culture has not yet been obtained, it should be obtained by clean catch, or by catheterization if a clean catch sample cannot be obtained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some clinicians ask patient to perform a perineal pad test, ie, collection of urine in a perineal pad for 1 to 24 hours has been used by some clinicians as part of the evaluation of women with SUI. However, we do not use this test in our practice, since it does not impact patient management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     URODYNAMIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urodynamic evaluation is rarely associated with adverse effects. The main disadvantages of urodynamic testing are that it is expensive, time-consuming, and causes patient discomfort. Cost-effectiveness analyses based upon United States expense data have reported that urodynamic testing compared with office evaluation would add expense and may not improve treatment outcomes in women with uncomplicated stress urinary incontinence (SUI) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/58/17319/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. There is no evidence that preoperative urodynamics improve treatment outcomes in women with uncomplicated SUI. Urodynamic testing may be useful when symptoms are not consistent with physical examination findings or when there is suspicion of urinary tract fistula or ectopic ureter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Women with uncomplicated SUI",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been considerable debate regarding the diagnostic value and cost-effectiveness of routine urodynamic testing prior to anti-incontinence surgery in women with uncomplicated SUI [",
"    <a class=\"abstract\" href=\"UTD.htm?16/58/17319/abstract/15,18,20-23\">",
"     15,18,20-23",
"    </a>",
"    ]. Women with uncomplicated SUI are those who do not have the characteristics described in the next section.",
"   </p>",
"   <p>",
"    Performance of preoperative urodynamic testing in women with uncomplicated SUI does not appear to improve treatment outcomes. This was best illustrated by a randomized trial that included 603 women with uncomplicated SUI who were assigned to either urodynamic testing or office evaluation (consisting of a symptom questionnaire, urinary stress test, postvoid residual volume, urinalysis, and assessment of urethral mobility) prior to SUI treatment (93 percent of women were treated with a midurethral sling) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/58/17319/abstract/24\">",
"     24",
"    </a>",
"    ]. At 12-month follow-up, the rate of successful treatment was assessed with two questionnaires and found to be non-inferior (defined as a difference of less than 11 percent) in women who had urodynamic testing compared with office evaluation (both were 77 percent). Women who had urodynamic testing were significantly less likely to receive a diagnosis of overactive bladder and more likely to receive a diagnosis of voiding-phase dysfunction, but this did not result in significant differences in treatment selection or outcomes.",
"   </p>",
"   <p>",
"    The role of urodynamic testing is limited in this patient population. Urodynamic evaluation is not required to confirm the diagnosis of SUI in women with typical SUI symptoms and physical examination findings (urinary stress test consistent with SUI).",
"   </p>",
"   <p>",
"    Mixed urinary incontinence does not impact the choice of surgical procedure, and thus, these women do not require preoperative urodynamic evaluation. As noted above, these women should undergo a trial of pharmacologic therapy prior to surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43177?source=see_link&amp;anchor=H25#H25\">",
"     \"Stress urinary incontinence in women: Choosing a primary surgical procedure\", section on 'Mixed incontinence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Occult SUI, which refers to SUI that develops after pelvic reconstructive surgery in women with advanced pelvic organ prolapse, can usually be diagnosed by repeating the urinary stress test while the prolapse is reduced by the examiner. This can be performed during pelvic examination in the office setting; there is no evidence that urodynamic testing is required to detect occult SUI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1546?source=see_link&amp;anchor=H9#H9\">",
"     \"Pelvic organ prolapse and stress urinary incontinence in women: Combined surgical treatment\", section on 'Detecting occult incontinence'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2484759\">",
"    <span class=\"h2\">",
"     Women with complicated SUI",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a general consensus among surgeons who perform anti-incontinence surgery that preoperative urodynamic evaluation is required in women with complicated SUI. These include women with a clinical diagnosis of SUI (based upon history and urinary stress testing) who have the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prior anti-incontinence surgery",
"     </li>",
"     <li>",
"      Prior pelvic radiation &nbsp;",
"     </li>",
"     <li>",
"      Neurogenic lower urinary tract dysfunction (eg, due to spinal cord injury, multiple sclerosis)",
"     </li>",
"     <li>",
"      Suspicion of a non-stress etiology of urinary incontinence, suggested by the following components of the office evaluation:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Leakage of urine without exertion, particularly while standing",
"     </li>",
"     <li>",
"      Nocturia (&ge;2 episodes per night)",
"     </li>",
"     <li>",
"      Persistently elevated postvoid residual volume (PVR) (&ge;50 mL)",
"     </li>",
"     <li>",
"      Urinary stress test with leakage that is delayed, copious, and difficult to stop",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Women with these findings may have overflow incontinence, intrinsic sphincter deficiency, or other systemic or local causes of incontinence (eg, urethral diverticulum, issues with mobility). Women with delayed leakage on the urinary stress test may have detrusor overactivity incontinence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29929?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical presentation and diagnosis of urinary incontinence\", section on 'Types of urinary incontinence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mixed urinary incontinence (coexistent stress and urge incontinence) is common, and is not considered complicated SUI. However, prior to surgery, women with urge-predominant mixed incontinence should undergo a trial of treatment with medical therapy for urge symptoms to assess whether this reduces the number of incontinence episodes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43177?source=see_link&amp;anchor=H25#H25\">",
"     \"Stress urinary incontinence in women: Choosing a primary surgical procedure\", section on 'Mixed incontinence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Techniques for urodynamic testing are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32120?source=see_link\">",
"     \"Urodynamic evaluation of women with incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/16/9474?source=see_link\">",
"       \"Patient information: Urinary incontinence in women (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/19/19764?source=see_link\">",
"       \"Patient information: Urinary incontinence treatments for women (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stress urinary incontinence (SUI), the involuntary leakage of urine on effort or exertion, or on sneezing or coughing, affects 4 to 35 percent of women. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of SUI is made by a combination of history and urinary stress testing. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SUI often coexists with pelvic organ prolapse",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      anal incontinence. The preoperative evaluation should include assessment for these conditions, as they may alter surgical decision making. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The medical and voiding history are used to ensure that the patient's symptoms are consistent with SUI and to exclude a non-stress etiology of urinary incontinence. A focused medical history is taken to exclude local or systemic conditions that may cause or worsen urinary incontinence, and to assess surgical risk. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Medical and voiding history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During a urinary stress test (cough stress test), instantaneous leakage with cough suggests SUI, while delayed leakage suggests detrusor overactivity incontinence, especially if there is a large flow of leakage that is difficult for the patient to stop. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Urinary stress test'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Urethral hypermobility is present in most women who have SUI. The clinical value of testing for urethral hypermobility is uncertain. (See",
"      <a class=\"local\" href=\"#H1568119\">",
"       'Assessing urethral mobility'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preoperative urodynamics are not necessary for women with uncomplicated SUI. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Urodynamic testing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/58/17319/abstract/1\">",
"      Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003; 61:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/58/17319/abstract/2\">",
"      Luber KM. The definition, prevalence, and risk factors for stress urinary incontinence. Rev Urol 2004; 6 Suppl 3:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/58/17319/abstract/3\">",
"      DeLancey JO. Structural support of the urethra as it relates to stress urinary incontinence: the hammock hypothesis. Am J Obstet Gynecol 1994; 170:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/58/17319/abstract/4\">",
"      Jackson SL, Weber AM, Hull TL, et al. Fecal incontinence in women with urinary incontinence and pelvic organ prolapse. Obstet Gynecol 1997; 89:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/58/17319/abstract/5\">",
"      Meschia M, Buonaguidi A, Pifarotti P, et al. Prevalence of anal incontinence in women with symptoms of urinary incontinence and genital prolapse. Obstet Gynecol 2002; 100:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/58/17319/abstract/6\">",
"      Markland AD, Kraus SR, Richter HE, et al. Prevalence and risk factors of fecal incontinence in women undergoing stress incontinence surgery. Am J Obstet Gynecol 2007; 197:662.e1.",
"     </a>",
"    </li>",
"    <li>",
"     Swift, S, Barnes, D, Herron, A, Goodnight, W. Test-retest reliability of the cotton swab (Q-tip(R)) test in the evaluation of the incontinent female. Int Urogynecol J Pelvic Floor Dysfunct 2010; :[Epub ahead of print].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/58/17319/abstract/8\">",
"      Thorp JM, Jones LH, Wells E, Ananth CV. Assessment of pelvic floor function: a series of simple tests in nulliparous women. Int Urogynecol J Pelvic Floor Dysfunct 1996; 7:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/58/17319/abstract/9\">",
"      Salvatore S, Serati M, Uccella S, et al. Inter-observer reliability of three different methods of measuring urethrovesical mobility. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/58/17319/abstract/10\">",
"      Noblett K, Lane FL, Driskill CS. Does pelvic organ prolapse quantification exam predict urethral mobility in stages 0 and I prolapse? Int Urogynecol J Pelvic Floor Dysfunct 2005; 16:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/58/17319/abstract/11\">",
"      Mattison ME, Simsiman AJ, Menefee SA. Can urethral mobility be assessed using the pelvic organ prolapse quantification system? An analysis of the correlation between point Aa and Q-tip angle in varying stages of prolapse. Urology 2006; 68:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/58/17319/abstract/12\">",
"      Cogan SL, Weber AM, Hammel JP. Is urethral mobility really being assessed by the pelvic organ prolapse quantification (POP-Q) system? Obstet Gynecol 2002; 99:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/58/17319/abstract/13\">",
"      Larrieux JR, Balgobin S. Effect of anatomic urethral length on the correlation between the Q-tip test and descent at point Aa of the POP-Q system. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/58/17319/abstract/14\">",
"      Dalpiaz O, Curti P. Role of perineal ultrasound in the evaluation of urinary stress incontinence and pelvic organ prolapse: a systematic review. Neurourol Urodyn 2006; 25:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/58/17319/abstract/15\">",
"      American College of Obstetricians and Gynecologists. Urinary incontinence in women. Obstet Gynecol 2005; 105:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/58/17319/abstract/16\">",
"      Kleeman S, Goldwasser S, Vassallo B, Karram M. Predicting postoperative voiding efficiency after operation for incontinence and prolapse. Am J Obstet Gynecol 2002; 187:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/58/17319/abstract/17\">",
"      Foster RT Sr, Borawski KM, South MM, et al. A randomized, controlled trial evaluating 2 techniques of postoperative bladder testing after transvaginal surgery. Am J Obstet Gynecol 2007; 197:627.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/58/17319/abstract/18\">",
"      Weber AM, Walters MD. Cost-effectiveness of urodynamic testing before surgery for women with pelvic organ prolapse and stress urinary incontinence. Am J Obstet Gynecol 2000; 183:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/58/17319/abstract/19\">",
"      Weber AM, Taylor RJ, Wei JT, et al. The cost-effectiveness of preoperative testing (basic office assessment vs. urodynamics) for stress urinary incontinence in women. BJU Int 2002; 89:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/58/17319/abstract/20\">",
"      Rosier PF, Gajewski JB, Sand PK, et al. Executive summary: The International Consultation on Incontinence 2008--Committee on: \"Dynamic Testing\"; for urinary incontinence and for fecal incontinence. Part 1: Innovations in urodynamic techniques and urodynamic testing for signs and symptoms of urinary incontinence in female patients. Neurourol Urodyn 2010; 29:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/58/17319/abstract/21\">",
"      Wall LL, Wiskind AK, Taylor PA. Simple bladder filling with a cough stress test compared with subtracted cystometry for the diagnosis of urinary incontinence. Am J Obstet Gynecol 1994; 171:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/58/17319/abstract/22\">",
"      Abstracts of the American College of Obstetricians and Gynecologists 53rd Annual Clinical Meeting. May 7-11, 2005, San Francisco, California, USA. Obstet Gynecol 2005; 105:1S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/58/17319/abstract/23\">",
"      Kj&oslash;lhede P, Ryd&eacute;n G. Prognostic factors and long-term results of the Burch colposuspension. A retrospective study. Acta Obstet Gynecol Scand 1994; 73:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/58/17319/abstract/24\">",
"      Nager CW, Brubaker L, Litman HJ, et al. A randomized trial of urodynamic testing before stress-incontinence surgery. N Engl J Med 2012; 366:1987.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8088 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-6D749065E6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_58_17319=[""].join("\n");
var outline_f16_58_17319=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MEDICAL AND VOIDING HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PELVIC EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      OFFICE TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Urinary stress test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1568119\">",
"      Assessing urethral mobility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Postvoid residual volume",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Urine culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      URODYNAMIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Women with uncomplicated SUI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2484759\">",
"      Women with complicated SUI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/8088\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/8088|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/23/28021\" title=\"figure 1\">",
"      Voiding history question",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/30/4591\" title=\"figure 2\">",
"      Voiding diary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/8088|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/13/41179\" title=\"table 1A\">",
"      Reversible cause incontinence A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/55/10108\" title=\"table 1B\">",
"      Reversible cause incontinence B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/11/3261\" title=\"table 2\">",
"      Meds that worsen UI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40473?source=related_link\">",
"      An overview of the epidemiology, risk factors, clinical manifestations, and management of pelvic organ prolapse in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29929?source=related_link\">",
"      Clinical presentation and diagnosis of urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22458?source=related_link\">",
"      Fecal incontinence in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41735?source=related_link\">",
"      Overview of the principles of medical consultation and perioperative medicine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/16/9474?source=related_link\">",
"      Patient information: Urinary incontinence in women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/19/19764?source=related_link\">",
"      Patient information: Urinary incontinence treatments for women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/18/19753?source=related_link\">",
"      Pelvic floor disorders associated with pregnancy and childbirth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1546?source=related_link\">",
"      Pelvic organ prolapse and stress urinary incontinence in women: Combined surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/46/8937?source=related_link\">",
"      Pelvic organ prolapse in women: Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43177?source=related_link\">",
"      Stress urinary incontinence in women: Choosing a primary surgical procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/23/44409?source=related_link\">",
"      Stress urinary incontinence in women: Persistent/recurrent symptoms after surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42681?source=related_link\">",
"      The gynecologic history and pelvic examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=related_link\">",
"      Treatment of urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26873?source=related_link\">",
"      Urethral diverticulum in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32120?source=related_link\">",
"      Urodynamic evaluation of women with incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44792?source=related_link\">",
"      Urogenital tract fistulas in women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_58_17320="Paclitaxel: Drug information";
var content_f16_58_17320=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Paclitaxel: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/26/17829?source=see_link\">",
"    see \"Paclitaxel: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/3/33846?source=see_link\">",
"    see \"Paclitaxel: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F205582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Paclitaxel&reg;;",
"     </li>",
"     <li>",
"      Paclitaxel for Injection;",
"     </li>",
"     <li>",
"      Paclitaxel Injection USP",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F205627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Antimicrotubular;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Natural Source (Plant) Derivative;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Taxane Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F205586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premedication with dexamethasone (20 mg orally or I.V. at 12 and 6 hours",
"     <b>",
"      or",
"     </b>",
"     14 and 7 hours before the dose; reduce dexamethasone dose to 10 mg orally with advanced HIV disease), diphenhydramine (50 mg I.V. 30-60 minutes prior to the dose), and cimetidine, famotidine, or ranitidine (I.V. 30-60 minutes prior to the dose) is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Ovarian carcinoma:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     I.V.: 135-175 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 3 hours every 3 weeks",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     135 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 24 hours every 3 weeks",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     50-80 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 1-3 hours weekly",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1.4-4 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion for 14 days every 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intraperitoneal (unlabeled route): 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 8 of a 21-day treatment cycle for 6 cycles, in combination with I.V. paclitaxel and intraperitoneal cisplatin.",
"     <b>",
"      Note:",
"     </b>",
"     Administration of intraperitoneal paclitaxel should include the standard paclitaxel premedication regimen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Metastatic breast cancer:",
"     </b>",
"     I.V.: 175-250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 3 hours every 3 weeks",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-80 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     weekly",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.4-4 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion for 14 days every 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nonsmall cell lung carcinoma:",
"     </b>",
"     I.V.: 135 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 24 hours every 3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      AIDS-related Kaposi's sarcoma:",
"     </b>",
"     I.V.: 135 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 3 hours every 3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      or",
"     </b>",
"     100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 3 hours every 2 weeks",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F205587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F5528661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     There are no FDA-approved labeling guidelines for dosage adjustment in patients with renal impairment. Aronoff (2007) recommends no dosage adjustment necessary for adults with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F205588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     The FDA-approved labeling recommendations are based upon the patient's first course of therapy where the usual dose would be 135 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     dose over 24 hours or the 175 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     dose over 3 hours in patients with normal hepatic function. Dosage in subsequent courses should be based upon individual tolerance. Adjustments for other regimens are not available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     24-hour infusion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transaminases &lt;2 times upper limit of normal (ULN) and bilirubin level &le;1.5 mg/dL: 135 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transaminases 2-&lt;10 times ULN and bilirubin level &le;1.5 mg/dL: 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transaminases &lt;10 times ULN and bilirubin level 1.6-7.5 mg/dL: 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transaminases &ge;10 times ULN or bilirubin level &gt;7.5 mg/dL: Avoid use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     3-hour infusion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transaminases &lt;10 times ULN and bilirubin level &le;1.25 times ULN: 175 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transaminases &lt;10 times ULN and bilirubin level 1.26-2 times ULN: 135 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transaminases &lt;10 times ULN and bilirubin level 2.01-5 times ULN: 90 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transaminases &ge;10 times ULN or bilirubin level &gt;5 times ULN: Avoid use",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F205628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage modification for toxicity (solid tumors, including ovary, breast, and lung carcinoma):",
"     </b>",
"     Courses of paclitaxel should not be repeated until the neutrophil count is &ge;1500 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     and the platelet count is &ge;100,000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; reduce dosage by 20% for patients experiencing severe peripheral neuropathy or severe neutropenia (neutrophil &lt;500 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     for a week or longer)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage modification for immunosuppression in advanced HIV disease:",
"     </b>",
"     Paclitaxel should not be given to patients with HIV if the baseline or subsequent neutrophil count is &lt;1000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     . Additional modifications include: Reduce dosage of dexamethasone in premedication to 10 mg orally; reduce dosage by 20% in patients experiencing severe peripheral neuropathy or severe neutropenia (neutrophil &lt;500 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     for a week or longer); initiate concurrent hematopoietic growth factor (G-CSF) as clinically indicated",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F205555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 6 mg/mL (5 mL, 16.7 mL, 25 mL, 50 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F205541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F205560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Infuse over 1-96 hours. When administered as sequential infusions, taxane derivatives should be administered before platinum derivatives (cisplatin, carboplatin) to limit myelosuppression and to enhance efficacy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Premedication with dexamethasone (20 mg orally or I.V. at 12 and 6 hours",
"     <b>",
"      or",
"     </b>",
"     14 and 7 hours before the dose; reduce to 10 mg with advanced HIV disease), diphenhydramine (50 mg I.V. 30-60 minutes prior to the dose), and cimetidine 300  mg, famotidine 20 mg, or ranitidine 50 mg (I.V. 30-60 minutes prior to the dose) is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Administer I.V. infusion over 1-24 hours; infuse through a 0.22 micron in-line filter and nonsorbing administration set.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intraperitoneal: 1- to 2-hour infusion",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F205634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, amikacin, aminophylline, ampicillin/sulbactam, anidulafungin, bleomycin, butorphanol, calcium chloride, carboplatin, cefepime, cefotetan, ceftazidime, cimetidine, cisplatin, cladribine, cyclophosphamide, cytarabine, dacarbazine, dexamethasone sodium phosphate, diphenhydramine, doripenem, doxorubicin, droperidol, etoposide, etoposide phosphate, famotidine, floxuridine, fluconazole, fluorouracil, furosemide, ganciclovir, gemcitabine, gentamicin, granisetron, haloperidol, heparin, hydrocortisone sodium phosphate, hydrocortisone sodium succinate, hydromorphone, ifosfamide, linezolid, lorazepam, magnesium sulfate, mannitol, meperidine, mesna, methotrexate, metoclopramide, morphine, nalbuphine, ondansetron, ondansetron with ranitidine, oxaliplatin, palonosetron, pemetrexed, pentostatin, potassium chloride, prochlorperazine edisylate, propofol, ranitidine, sodium bicarbonate, thiotepa, topotecan, vancomycin, vinblastine, vincristine, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B, amphotericin B cholesteryl sulfate complex, chlorpromazine, doxorubicin liposome, hydroxyzine, methylprednisolone sodium succinate, mitoxantrone.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F205559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of breast, nonsmall cell lung, and ovarian cancers; treatment of AIDS-related Kaposi's sarcoma (KS)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F2685702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of bladder, cervical, small cell lung, and head and neck cancers; treatment of (unknown primary) adenocarcinoma",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F205636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       PACLitaxel may be confused with cabazitaxel, DOCEtaxel, PARoxetine, Paxil&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       PACLitaxel (conventional) may be confused with PACLitaxel  (protein-bound)",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Taxol&reg; may be confused with Abraxane&reg;, Paxil&reg;, Taxotere&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F205625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Percentages reported with single-agent therapy.",
"     <b>",
"      Note:",
"     </b>",
"     Myelosuppression is dose related, schedule related, and infusion-rate dependent (increased incidences with higher doses, more frequent doses, and longer infusion times) and, in general, rapidly reversible upon discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Flushing (28%), ECG abnormal (14% to 23%), edema (21%), hypotension (4% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia (87%), rash (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea/vomiting (52%), diarrhea (38%), mucositis (17% to 35%; grades 3/4: up to 3%), stomatitis (15%; most common at doses &gt;390 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),  abdominal pain (with intraperitoneal paclitaxel)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Neutropenia (78% to 98%; grade 4: 14% to 75%; onset 8-10 days, median nadir 11 days, recovery 15-21 days), leukopenia (90%; grade 4: 17%), anemia (47% to 90%; grades 3/4: 2% to 16%), thrombocytopenia (4% to 20%; grades 3/4: 1% to 7%), bleeding (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased (22%), AST increased (19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reaction (erythema, tenderness, skin discoloration, swelling: 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Peripheral neuropathy (42% to 70%; grades 3/4: up to 7%), arthralgia/myalgia (60%), weakness (17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Creatinine increased (observed in KS patients only: 18% to 34%; severe: 5% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity reaction (31% to 45%; grades 3/4: up to 2%), infection (15% to 30%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Bradycardia (3%), tachycardia (2%), hypertension (1%), rhythm abnormalities (1%), syncope (1%), venous thrombosis (1%)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Nail changes (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Febrile neutropenia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Bilirubin increased (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylaxis, arrhythmia, ataxia, atrial fibrillation, AV block, back pain, cardiac conduction abnormalities, cellulitis, CHF, chills, conjunctivitis, dehydration, enterocolitis, extravasation recall, hepatic encephalopathy, hepatic necrosis, induration, intestinal obstruction, intestinal perforation, interstitial pneumonia, ischemic colitis, lacrimation increased, maculopapular rash, malaise, MI, myocardial ischemia, necrotic changes and ulceration following extravasation, neuroencephalopathy, neutropenic enterocolitis, neutropenic typhlitis, ototoxicity (tinnitus and hearing loss), pancreatitis, paralytic ileus, phlebitis, pneumonitis, pruritus, pulmonary embolism, pulmonary fibrosis, radiation recall, radiation pneumonitis, renal insufficiency, seizure, skin exfoliation, skin fibrosis, skin necrosis, Stevens-Johnson syndrome, supraventricular tachycardia, toxic epidermal necrolysis, ventricular tachycardia (asymptomatic), visual disturbances (scintillating scotomata)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F205563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to paclitaxel, Cremophor&reg; EL (polyoxyethylated castor oil), or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F205545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression:",
"     <b>",
"      [U.S. Boxed Warning]: Bone marrow suppression is the dose-limiting toxicity; do not administer if baseline absolute neutrophil count (ANC) is &lt;1500 cells/mm",
"      <sup>",
"       3",
"      </sup>",
"      (&lt;1000 cells/mm",
"      <sup>",
"       3",
"      </sup>",
"      for patients with AIDS-related KS);",
"     </b>",
"     reduce future doses by 20% for severe neutropenia (&lt;500 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     for 7 days or more) and consider the use of supportive therapy, including growth factor treatment. When administered as sequential infusions, taxane derivatives (docetaxel, paclitaxel) should be administered before platinum derivatives (carboplatin, cisplatin) to limit myelosuppression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular effects: Infusion-related hypotension, bradycardia, and/or hypertension may occur; frequent monitoring of vital signs is recommended, especially during the first hour of the infusion. Rare but severe conduction abnormalities have been reported; conduct cardiac monitoring during subsequent infusions for these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions:",
"     <b>",
"      [U.S. Boxed Warning]: Severe hypersensitivity reactions have been reported;",
"     </b>",
"     premedication may minimize this effect. Stop infusion and do not rechallenge for severe hypersensitivity reactions (hypotension requiring treatment, dyspnea requiring bronchodilators, angioedema, urticaria). Minor hypersensitivity reactions (flushing, skin reactions, dyspnea, hypotension, or tachycardia) do not require interruption of treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral neuropathy: With use, peripheral neuropathy may occur; patients with pre-existing neuropathies from chemotherapy or coexisting conditions (eg, diabetes mellitus) may be at a higher risk; reduce dose by 20% for severe neuropathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with extreme caution in patients with hepatic dysfunction (myelotoxicity may be worsened); dose reductions are recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; increased risk of toxicity (neutropenia, neuropathy).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dehydrated alcohol: Formulations contain dehydrated alcohol; may cause adverse CNS effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F205622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C8 (major), CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Induces",
"     </b>",
"     CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F205549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antineoplastic Agents (Anthracycline, Systemic): Taxane Derivatives may enhance the adverse/toxic effect of Antineoplastic Agents (Anthracycline, Systemic). Taxane Derivatives may increase the serum concentration of Antineoplastic Agents (Anthracycline, Systemic). Taxane Derivatives may also increase the formation of toxic anthracycline metabolites in heart tissue.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bexarotene (Systemic): May decrease the serum concentration of PACLitaxel. PACLitaxel may increase the serum concentration of Bexarotene (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inducers (Strong): May increase the metabolism of CYP2C8 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inhibitors (Moderate): May decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inhibitors (Strong): May decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOXOrubicin: Taxane Derivatives may decrease the metabolism of DOXOrubicin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C8 Substrates. Management: Use CYP2C8 substrates at the lowest recommended dose, and monitor closely for adverse effects (including myopathy), during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Platinum Derivatives: May enhance the myelosuppressive effect of Taxane Derivatives. Administer Taxane derivative before Platinum derivative when given as sequential infusions to limit toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reverse Transcriptase Inhibitors (Non-Nucleoside): May decrease the metabolism of PACLitaxel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: May enhance the adverse/toxic effect of PACLitaxel. Management: Concurrent sorafenib with carboplatin and paclitaxel in patients with squamous cell lung cancer is contraindicated.  Use in other settings is not specifically contraindicated but should be approached with added caution.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: PACLitaxel may increase the serum concentration of Trastuzumab. Trastuzumab may decrease the serum concentration of PACLitaxel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vinorelbine: PACLitaxel may enhance the neurotoxic effect of Vinorelbine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F205577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid black cohosh, dong quai in estrogen-dependent tumors. Avoid valerian, St John's wort (may decrease paclitaxel levels), kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F205551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F205566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events (embryotoxicity, fetal toxicity, and maternal toxicity) have been observed in animal reproduction studies at doses less than the recommended human dose. An",
"     <i>",
"      ex vivo",
"     </i>",
"     human placenta perfusion model illustrated that paclitaxel crossed the placenta at term. Placental transfer was low and affected by the presence of albumin; higher albumin concentrations resulted in lower paclitaxel placental transfer (Berveiller, 2012). Women of childbearing potential should be advised to avoid becoming pregnant. A pregnancy registry is available for all cancers diagnosed during pregnancy at Cooper Health (877-635-4499).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F205596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F205567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Paclitaxel is excreted in breast milk (case report). The mother (3 months postpartum) was treated with paclitaxel 30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (56.1 mg) and carboplatin once weekly for papillary thyroid cancer. Milk samples were obtained 4-316 hours after the infusion given at the sixth and final week of therapy. The average paclitaxel milk concentration over the testing interval was 0.78 mg/L. Although maternal serum concentrations were not noted in the report, the relative infant dose to a nursing infant was calculated to be ~17% of the maternal dose. Paclitaxel continued to be detected in breast milk when sampled at 172 hours after the dose and was below the limit of detection when sampled at 316 hours after the infusion (Griffin, 2012). Due to the potential for serious adverse reactions in a nursing infant, breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Concentrate",
"     </b>",
"     (PACLitaxel Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg/5 mL (5 mL): $20.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/16.7 mL (16.7 mL): $67.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg/25 mL (25 mL): $79.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg/50 mL (50 mL): $156.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F205553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelet count, liver and kidney function; monitor for hypersensitivity reactions, vital signs (frequently during the first hour of infusion), continuous cardiac monitoring (patients with conduction abnormalities)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F205556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mean maximum serum concentrations: 435-802 ng/mL following 24-hour infusions of 200-275 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     and were approximately 10% to 30% of those following 6-hour infusions of equivalent doses",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F205568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aclipak (SG);",
"     </li>",
"     <li>",
"      Aclixel (MX);",
"     </li>",
"     <li>",
"      Alzene (CO);",
"     </li>",
"     <li>",
"      Anzatax (AU, BR, HK, KP, MY, NZ, SG, TH, TW);",
"     </li>",
"     <li>",
"      Asotax (AR, MX);",
"     </li>",
"     <li>",
"      Biotax (IL);",
"     </li>",
"     <li>",
"      Bristaxol (MX);",
"     </li>",
"     <li>",
"      Britaxol (CN);",
"     </li>",
"     <li>",
"      Clitaxel (VE);",
"     </li>",
"     <li>",
"      Cryoxet (MX);",
"     </li>",
"     <li>",
"      Dalys (PE);",
"     </li>",
"     <li>",
"      Ebetaxel (HK, ID, IL, SG);",
"     </li>",
"     <li>",
"      Genaxol (TW);",
"     </li>",
"     <li>",
"      Genetaxyl (TH);",
"     </li>",
"     <li>",
"      Genexol (KP);",
"     </li>",
"     <li>",
"      Intaxel (IN, TH);",
"     </li>",
"     <li>",
"      Meditaxel (PE);",
"     </li>",
"     <li>",
"      Paclitaxin (TH);",
"     </li>",
"     <li>",
"      Pacxel (KP);",
"     </li>",
"     <li>",
"      Padexol (KP);",
"     </li>",
"     <li>",
"      Panataxel (EC);",
"     </li>",
"     <li>",
"      Parexel (CO, PY);",
"     </li>",
"     <li>",
"      Paxel (KP, PH);",
"     </li>",
"     <li>",
"      Paxene (AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, IE, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR);",
"     </li>",
"     <li>",
"      Paxus (ID);",
"     </li>",
"     <li>",
"      Praxel (CN, MX, TH);",
"     </li>",
"     <li>",
"      Sindaxel (BG, HK, ID, TH);",
"     </li>",
"     <li>",
"      Taxocris (UY);",
"     </li>",
"     <li>",
"      Taxol (AR, AT, AU, BE, CH, CL, CO, CZ, DE, DK, EE, ES, FI, FR, GR, HK, HN, IT, KP, NL, NO, NZ, PK, PL, RU, SE, TH, TR, ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F205544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Paclitaxel promotes microtubule assembly by enhancing the action of tubulin dimers, stabilizing existing microtubules, and inhibiting their disassembly, interfering with the late G",
"     <sub>",
"      2",
"     </sub>",
"     mitotic phase, and inhibiting cell replication. In addition, the drug can distort mitotic spindles, resulting in the breakage of chromosomes. Paclitaxel may also suppress cell proliferation and modulate immune response.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F205562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : Widely distributed into body fluids and tissues; affected by dose and duration of infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      dss",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1- to 6-hour infusion: 67.1 L/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     24-hour infusion: 227-688 L/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 89% to 98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP2C8 and 3A4; forms metabolites (primarily 6&alpha;-hydroxypaclitaxel)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1- to 6-hour infusion: Mean (beta): 6.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3-hour infusion: Mean (terminal): 13.1-20.2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     24-hour infusion: Mean (terminal): 15.7-52.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (~70%, 5% as unchanged drug); urine (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Mean: Total body: After 1- and 6-hour infusions: 5.8-16.3 L/hour/m",
"     <sup>",
"      2",
"     </sup>",
"     ; After 24-hour infusions: 14.2-17.2 L/hour/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Armstrong DK, Bundy B, Wenzel L, et al, &ldquo;Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(1):34-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/58/17320/abstract-text/16394300/pubmed\" id=\"16394300\" target=\"_blank\">",
"        16394300",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 101.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baker AF and Dorr RT, &ldquo;Drug Interactions With the Taxanes: Clinical Implications,&rdquo;",
"      <i>",
"       Cancer Treat Rev",
"      </i>",
"      , 2001, 27(4):221-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/58/17320/abstract-text/11545542/pubmed\" id=\"11545542\" target=\"_blank\">",
"        11545542",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berveiller P, Vinot C, Mir O, et al, \"Comparative Transplacental Transfer of Taxanes Using the Human Perfused Cotyledon Placental Model,\"",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 2012, 207(6):514.e1-514.e7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/58/17320/abstract-text/23174392/pubmed\" id=\"23174392\" target=\"_blank\">",
"        23174392",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Floyd JD, Nguyen DT, Lobins RL, et al, &ldquo;Cardiotoxicity of Cancer Therapy,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(30):7685-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/58/17320/abstract-text/16234530/pubmed\" id=\"16234530\" target=\"_blank\">",
"        16234530",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Griffin SJ, Milla M, Baker TE, et al, \"Transfer of Carboplatin and Paclitaxel into Breast Milk,\"",
"      <i>",
"       J Hum Lact",
"      </i>",
"      , 2012, 28(4):457-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/58/17320/abstract-text/23087196/pubmed\" id=\"23087196\" target=\"_blank\">",
"        23087196",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hanioka N, Matsumoto K, Saito Y, et al, &ldquo;Functional Characterization of CYP2C8.13 and CYP2C8.14: Catalytic Activities Toward Paclitaxel,\"",
"      <i>",
"       Basic Clin Pharmacol Toxicol",
"      </i>",
"      , 2010, 107(1):565-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/58/17320/abstract-text/20148860/pubmed\" id=\"20148860\" target=\"_blank\">",
"        20148860",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hesketh PJ, Kris MG, Grunberg SM, et al, &ldquo;Proposal for Classifying the Acute Emetogenicity of Cancer Chemotherapy,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1997, 15(1):103-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/58/17320/abstract-text/8996130/pubmed\" id=\"8996130\" target=\"_blank\">",
"        8996130",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holmes FA, &ldquo;Paclitaxel Combination Therapy in the Treatment of Metastatic Breast Cancer: A Review,&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 1996, 23(5 Suppl 11):46-56.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Janus N, Thariat J, Boulanger H, et al, &ldquo;Proposal for Dosage Adjustment and Timing of Chemotherapy in Hemodialyzed Patients,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2010, 21(7):1395-403.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/58/17320/abstract-text/20118214/pubmed\" id=\"20118214\" target=\"_blank\">",
"        20118214",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Longnecker SM, Donehower RC, Cates AE, et al, &ldquo;High-Performance Liquid Chromatographic Assay for Taxol in Human Plasma and Urine and Pharmacokinetics in a Phase I Trial,&rdquo;",
"      <i>",
"       Cancer Treat Rep",
"      </i>",
"      , 1987, 71(1):53-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/58/17320/abstract-text/2878719/pubmed\" id=\"2878719\" target=\"_blank\">",
"        2878719",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mekhail TM and Markman M, &ldquo;Paclitaxel in Cancer Therapy,&rdquo;",
"      <i>",
"       Expert Opin Pharmacother",
"      </i>",
"      , 2002, 3(6):755-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/58/17320/abstract-text/12036415/pubmed\" id=\"12036415\" target=\"_blank\">",
"        12036415",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miller K, Wang M, Gralow J, et al, &ldquo;Paclitaxel Plus Bevacizumab Versus Paclitaxel Alone for Metastatic Breast Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 357(26):2666-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/58/17320/abstract-text/18160686/pubmed\" id=\"18160686\" target=\"_blank\">",
"        18160686",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgan C, Tillett T, Braybrooke J, et al, &ldquo;Management of Uncommon Chemotherapy-Induced Emergencies,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2011, 12(8):806-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/58/17320/abstract-text/21276754/pubmed\" id=\"21276754\" target=\"_blank\">",
"        21276754",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      P&eacute;rez Fidalgo JA, Garc&iacute;a Fabregat L, Cervantes A, et al, &ldquo;Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2012, 23(Suppl 7):167-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/58/17320/abstract-text/22997449/pubmed\" id=\"22997449\" target=\"_blank\">",
"        22997449",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rowinsky EK and Donehower RC, &ldquo;Paclitaxel (Taxol),&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995,  332(15):1004-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/58/17320/abstract-text/7885406/pubmed\" id=\"7885406\" target=\"_blank\">",
"        7885406",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rowinsky EK, &ldquo;The Taxanes: Dosing and Scheduling Considerations,&rdquo;",
"      <i>",
"       Oncology",
"      </i>",
"      , 1997, 11(3 Suppl 2):7-19.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Seetalarom K, Kudelka AP, Verschraegen CF, et al, &ldquo;Taxanes in Ovarian Cancer Treatment,&rdquo;",
"      <i>",
"       Curr Opin Obstet Gynecol",
"      </i>",
"      , 1997, 9(1):14-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/58/17320/abstract-text/9090476/pubmed\" id=\"9090476\" target=\"_blank\">",
"        9090476",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sonnichsen DS and Relling MV, &ldquo;Clinical Pharmacokinetics of Paclitaxel,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1994, 27(4):256-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/58/17320/abstract-text/7834963/pubmed\" id=\"7834963\" target=\"_blank\">",
"        7834963",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spencer CM and Faulds D, &ldquo;Paclitaxel. A Review of Its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Potential in the Treatment of Cancer,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1994, 48(5):794-847.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/58/17320/abstract-text/7530632/pubmed\" id=\"7530632\" target=\"_blank\">",
"        7530632",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9735 Version 50.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-219.243.220.100-C38B34FA94-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_58_17320=[""].join("\n");
var outline_f16_58_17320=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709191\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205582\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205627\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205586\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205587\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5528661\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205588\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205628\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205555\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205541\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205560\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205634\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205559\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2685702\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205636\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205625\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205563\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205545\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205622\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205549\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205577\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205551\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205566\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205596\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205567\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323590\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205553\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205556\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205568\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205544\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205562\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9735\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9735|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/26/17829?source=related_link\">",
"      Paclitaxel: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/3/33846?source=related_link\">",
"      Paclitaxel: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_58_17321="Basic vertebral anatomy";
var content_f16_58_17321=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F58088&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F58088&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 626px\">",
"   <div class=\"ttl\">",
"    Basic vertebral anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 606px; height: 456px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A \"typical\" vertebra, represented by L2.",
"    <br>",
"     (A) Functional components include the vertebral body (bone color), a vertebral arch (red), and seven processes: three for muscle attachment and leverage (blue) and four that participate in synovial joints with adjacent vertebrae (yellow).",
"     <br>",
"      (B, C) Bony formations of the vertebrae are demonstrated. The vertebral foramen is bounded by the vertebral arch and body. A small superior vertebral notch and a larger inferior vertebral notch flank the pedicle.",
"      <br>",
"       (D) The superior and inferior notches of adjacent vertebrae plus the IV disc that unites them form the IV foramen for the passage of a spinal nerve and its accompanying vessels. Note that each articular process has an articular facet where contact occurs with the articular facets of adjacent vertebrae (B-D).",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"        Reproduced with permission from: Moore KL, Dalley AF. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"       </div>",
"       <div class=\"contractual\">",
"        <br/>",
"        <a href=\"file://www.lww.com\">",
"         file://www.lww.com",
"        </a>",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_58_17321=[""].join("\n");
var outline_f16_58_17321=null;
var title_f16_58_17322="Infil UC lymphoepith-like";
var content_f16_58_17322=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F79184&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F79184&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Infiltrating urothelial carcinoma, lymphoepithelioma-like variant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The lymphoepithelioma-like variant of urothelial carcinoma is characterized by sheets of undifferentiated cells with large nuclei and poorly defined cytoplasmic borders in a prominent inflammatory background.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cristina Magi-Galluzzi, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_58_17322=[""].join("\n");
var outline_f16_58_17322=null;
var title_f16_58_17323="IDUS vs EUS for resectability";
var content_f16_58_17323=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F72258&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F72258&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Rates of detection of biliary obstruction, prediction of resectability, and T-stage by endoscopic ultrasound (EUS) and intraductal ultrasound (IDUS)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Determine cause biliary obstruction",
"       </td>",
"       <td class=\"subtitle1\">",
"        Correct prediction of resectability",
"       </td>",
"       <td class=\"subtitle1\">",
"        Correct T-staging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         EUS",
"        </strong>",
"       </td>",
"       <td>",
"        80 percent",
"       </td>",
"       <td>",
"        76 percent",
"       </td>",
"       <td>",
"        54 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         IDUS",
"        </strong>",
"       </td>",
"       <td>",
"        98 percent",
"       </td>",
"       <td>",
"        82 percent",
"       </td>",
"       <td>",
"        78 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         p value",
"        </strong>",
"       </td>",
"       <td>",
"        &lt;0.001",
"       </td>",
"       <td>",
"        &lt;0.002",
"       </td>",
"       <td>",
"        &lt;0.001",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Menzel J, Poremba C, Dietl KH, Domschke W. Scand J Gastroenterol 2000; 35:77.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_58_17323=[""].join("\n");
var outline_f16_58_17323=null;
var title_f16_58_17324="Characteristics of chromosomal breakage syndromes";
var content_f16_58_17324=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F82574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F82574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Characteristics of chromosomal breakage syndromes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Immunodeficiency",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cancer predisposition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ataxia-telangiectasia",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ataxia-telangiectasia like disorder",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bloom syndrome",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nijmegen breakage syndrome",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fanconi's anemia",
"       </td>",
"       <td class=\"centered\">",
"        &plusmn;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immunodeficiency/centrometric instability/facial anomalies syndrome",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cockaynes syndromes",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trichothiodystrophy",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Xeroderma pigmentosa",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DNA ligase I deficiency",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PMS2 deficiency",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DNA recombinase repair defects (DNA-PKcs, Artemis, DNA ligase 4, Cernunnos/XLF)",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        ?",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Howard M Lederman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_58_17324=[""].join("\n");
var outline_f16_58_17324=null;
var title_f16_58_17325="NASCET endarterectomy stroke death";
var content_f16_58_17325=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F67964&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F67964&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Carotid endarterectomy reduces major stroke and death in symptomatic patients with severe stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 256px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The North American Symptomatic Carotid Endarterectomy Trial (NASCET)&nbsp;included 659 patients with a recent transient ischemic attack or nondisabling stroke and a 70 to 99 percent carotid stenosis who were randomly assigned to carotid endarterectomy or medical therapy. At two year follow-up, the cumulative risk of a major stroke or death was significantly lower in the endarterectomy group compared with the medical treatment group (8.0 versus 19.1 percent). The Kaplan-Meier survival curve shows the probability of event-free survival after randomization at six month intervals.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 1991; 325:445.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_58_17325=[""].join("\n");
var outline_f16_58_17325=null;
var title_f16_58_17326="Corticosteroid drug interact";
var content_f16_58_17326=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F53228&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F53228&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major drug interactions with systemic glucocorticoids*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Interacting class",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sample agents",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effect",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Co-administration of drugs that are strong inducers of CYP 3A may DECREASE glucocorticoid exposure and efficacy",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anticonvulsants",
"       </td>",
"       <td>",
"        Carbamazepine, fosphenytoin, oxcarbazepine, pentobarbital, phenobarbital, phenytoin, primidone",
"       </td>",
"       <td rowspan=\"3\">",
"        Reduced glucocorticoid effects due to accelerated clearance. Maximal effect of interaction occurs approximately two weeks after initiating a strong CYP inducer. Induction effects may persist for weeks following discontinuation of a strong CYP inducer.",
"       </td>",
"       <td>",
"        Methylprednisolone clearance may be increased by &gt;200 percent by interacting anticonvulsants, significantly decreasing glucocorticoid exposure. Dose alteration of methylprednisolone may be needed. Prednisone and prednisolone are affected considerably less by this interaction.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anti-infectives",
"       </td>",
"       <td>",
"        Efavirenz, etravirine, nafcillin, nevirapine, rifampin, rifabutin, rifapentine",
"       </td>",
"       <td>",
"        Methylprednisolone, prednisone, and prednisolone exposure may be decreased by as much as 60 percent following rifampin co-administration. Rifampin interacts more significantly than rifabutin or rifapentine.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Other",
"       </td>",
"       <td>",
"        Bosentan, St. John's wort",
"       </td>",
"       <td>",
"        Reduced glucocorticoid exposure is possible. However, no clinical data are available.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Orally administered antacids may decrease bioavailability of orally administered glucocorticoids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Oral antacids",
"       </td>",
"       <td>",
"        Aluminum hydroxide, calcium carbonate, magnesium hydroxide, others",
"       </td>",
"       <td>",
"        Potentially reduced glucocorticoid effects due to decreased oral absorption. Variable effects reported.",
"       </td>",
"       <td>",
"        Separating administration of oral glucocorticoids from antacids by two or more hours may minimize this interaction.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Co-administration of drugs that are strong inhibitors of CYP 3A and/or P-gp may INCREASE glucocorticoid exposure and toxicity",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Antibiotics",
"       </td>",
"       <td>",
"        Clarithromycin, telithromycin",
"       </td>",
"       <td rowspan=\"4\">",
"        Increased glucocorticoid effects due to decreased clearance",
"       </td>",
"       <td rowspan=\"4\">",
"        <p>",
"         Methylprednisolone and dexamethasone clearance may be reduced by approximately 30 to 50 percent. Monitor biomarkers for exaggerated glucocorticoid effects.",
"         <sup>",
"          &Delta;",
"         </sup>",
"         Dose alteration of methylprednisolone and dexamethasone may be needed. No specific recommendation available.",
"        </p>",
"        <p>",
"         Prednisone and prednisolone are not affected to a clinically relevant degree by this interaction.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Antifungals",
"       </td>",
"       <td>",
"        Itraconazole, ketoconazole, posaconazole, voriconazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Antimycobacterial",
"       </td>",
"       <td>",
"        Isoniazid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Antivirals (including HIV and HCV)",
"       </td>",
"       <td>",
"        Atazanavir, boceprevir, darunavir, delavirdine, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, telaprevir",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Estrogens",
"       </td>",
"       <td>",
"        Estrogen containing oral contraceptives, conjugated estrogens, esterified estrogens, others",
"       </td>",
"       <td>",
"        Estrogens can significantly increase glucocorticoid exposure and effects. This may be due to alteration of steroid metabolism and protein binding.",
"       </td>",
"       <td>",
"        Monitor biomarkers for exaggerated glucocorticoid effects.",
"        <sup>",
"         &Delta;",
"        </sup>",
"        Dose alteration of glucocorticoid may be needed. No specific recommendation available.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Immunosuppressants",
"       </td>",
"       <td>",
"        Cyclosporine, tacrolimus, everolimus",
"       </td>",
"       <td>",
"        Increased exposure to methylprednisolone, prednisone, and prednisolone. Other effects described include increased and decreased cyclosporine concentrations and decreased everolimus concentrations with dexamethasone.",
"       </td>",
"       <td>",
"        <p>",
"         Monitor biomarkers for exaggerated glucocorticoid effects.",
"         <sup>",
"          &Delta;",
"         </sup>",
"         Dose alteration may be needed. No specific recommendation available.",
"        </p>",
"        <p>",
"         Monitor immunosuppressant concentrations closely. If possible, avoid dexamethasone with everolimus. For additional information see \"Pharmacology and side effects of cyclosporine and tacrolimus.\"",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Multiple effects or additive toxicities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anticoagulants, oral",
"       </td>",
"       <td>",
"        Warfarin",
"       </td>",
"       <td>",
"        Glucocorticoids may increase anticoagulant effect of warfarin by multiple mechanisms",
"       </td>",
"       <td>",
"        Most patients stabilized on warfarin will require a significant alteration in warfarin dose within three to seven days after initiating glucocorticoid. Monitor INR closely to determine need for dose adjustment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diuretics, potassium wasting",
"       </td>",
"       <td>",
"        Furosemide, hydrochlorothiazide, others",
"       </td>",
"       <td>",
"        Glucocorticoids may enhance the kaluretic effects of potassium wasting diuretics",
"       </td>",
"       <td>",
"        Evaluate serum potassium levels to determine whether alteration of diuretic therapy and/or potassium supplementation is needed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fluoroquinolone anti-infectives",
"       </td>",
"       <td>",
"        Ciprofloxacin, gemifloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, others",
"       </td>",
"       <td>",
"        Increased risk of developing tendonitis and rupture",
"       </td>",
"       <td>",
"        Monitor for new onset tendon and/or joint pain. Use fluoroquinolones with glucocorticoids cautiously in older adults and children.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypoglycemic agents (oral and insulin)",
"       </td>",
"       <td>",
"        Acarbose, glipizide, glyburide, insulins, metformin, pioglitazone, sitagliptin, others",
"       </td>",
"       <td>",
"        Initiation of glucocorticoid treatment may result in glucose dysregulation",
"       </td>",
"       <td>",
"        Closely monitor blood glucose in patients at risk for glycemic dysregulation. Adjust hypoglycemic agents based on blood glucose results.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nonsteroidal antiinflammatory drugs (NSAIDs)",
"       </td>",
"       <td>",
"        Ibuprofen, indomethacin, ketorolac, ketoprofen, naproxen, others",
"       </td>",
"       <td>",
"        Increased risk of peptic ulcer disease when glucocorticoids are used in combination with an NSAID, compared with the use of either alone",
"       </td>",
"       <td>",
"        See \"Major side effects of systemic glucocorticoids,\" section 'Gastrointestinal tract.'",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    This table does not show all possible interactions. For additional interactions and information including management suggestions, see Lexi-Interact&trade; program included with UpToDate. Interaction data and recommendations refer to systemic drug forms.",
"    <div class=\"footnotes\">",
"     CYP 3A4: cytochrome P450 3A4; P-gp: P-glycoprotein efflux membrane transporters; HCV: hepatitis C virus; HIV: human immunodeficiency virus; NSAID: nonsteroidal antiinflammatory drug; INR: international normalized ratio.",
"     <br>",
"      * No significant interactions with azathioprine, methotrexate, histamine",
"      <sub>",
"       2",
"      </sub>",
"      antagonists (eg, famotidine, cimetidine, ranitidine), or proton pump inhibitors (eg, omeprazole, pantoprazole, rabeprazole).",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       For a list of CYP 3A4 inducers/inhibitors, see other table: \"Inhibitors and inducers of cytochrome P450 3A4.\"",
"       <br>",
"        &Delta; Biomarkers of glucocorticoid toxicity may include neuropsychiatric reactions, fluid and electrolyte disturbances, hypertension, and/or hyperglycemia.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Czock D, et al. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids; Clin Pharmacokinet 2005; 44:61. Lexicomp Online. Copyright &copy; 1978-2013 Lexicomp, Inc. All Rights Reserved; Wynn GH, et al (Eds). Clinical Manual of Drug Interaction Principles for Medical Practice APA publishing, Washington DC. Copyright &copy; 2009.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_58_17326=[""].join("\n");
var outline_f16_58_17326=null;
var title_f16_58_17327="M streptocerca microfilariae";
var content_f16_58_17327=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F83931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F83931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    M. streptocerca microfilariae",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 245px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Microfilaria of M. streptocerca fixed in 2% formalin and stained with hematoxylin. Microfilariae of Mansonella streptocerca are unsheathed and measure 180 to 240 micrometers. The tail is been into a hook-like shape, and the nuclei extend to the end of the tail. Microfilariae are found in skin and do not circulate in the blood.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Filariasis. Available at:",
"     <a href=\"file://www.dpd.cdc.gov/dpdx/html/imagelibrary/Filariasis_il.htm\" style=\"font-style: italic;\" target=\"_blank\">",
"      file://www.dpd.cdc.gov/dpdx/html/imagelibrary/Filariasis_il.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_58_17327=[""].join("\n");
var outline_f16_58_17327=null;
